Hepatic gap junctions in the hepatocarcinogen-resistant DRH rat

Area of Science:

• Hepatology
• Carcinogenesis Research
• Cellular Biology

Background:

• Gap junctions (connexins) play a dual role in cancer, acting as both tumor suppressors and promoters.
• Hepatocarcinogen-resistant (DRH) rats offer a model to study mechanisms of cancer resistance in the liver.

Purpose of the Study:

• To investigate the structure and expression of hepatic gap junctions and connexin 32 (Cx32) in DRH rats.
• To determine the response of hepatic gap junctions to the hepatocarcinogen 3'-methyl-4-dimethylaminoazobenzene (3'-MeDAB).

Main Methods:

• Comparative analysis of hepatic gap junctions and Cx32 expression in DRH and control Donryu rats.
• Morphometry, immunohistochemistry, and immunoblotting were used to assess gap junction structure and protein levels.
• Evaluation of cathepsin D and mitogen-activated protein kinase expression following 3'-MeDAB treatment.

Main Results:

• DRH rats showed higher basal levels of hepatic gap junctions and Cx32 protein compared to Donryu rats.
• While Donryu rats exhibited increased gap junctions and Cx32 upon 3'-MeDAB exposure, DRH rats did not.
• DRH rats demonstrated resistance to 3'-MeDAB toxicity, indicated by stable liver weight and lower cathepsin D induction.

Conclusions:

• Stabilized hepatic gap junctions in DRH rats contribute to their resistance against 3'-MeDAB-induced carcinogenesis.
• Coordinated metabolic coupling via gap junctions may be a mechanism for evading chemical toxicity.
• Connexin-mediated gap junction function is crucial for liver cancer prevention.